Poxel Toekomstige groei

Future criteriumcontroles 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Poxel.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Biotechs winstgroei	8.4%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Recent updates

Poxel S.A. (EPA:POXEL) Analysts Just Trimmed Their Revenue Forecasts By 28%

Mar 27

Is Poxel (EPA:POXEL) Weighed On By Its Debt Load?

May 07

How Much Did Poxel's(EPA:POXEL) Shareholders Earn From Share Price Movements Over The Last Five Years?

Dec 16

How Does Poxel's (EPA:POXEL) CEO Pay Compare With Company Performance?

Nov 17

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Poxel onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

ENXTPA:POXEL - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2023	2	-35	-14	-14	N/A
9/30/2023	2	-40	-15	-15	N/A
6/30/2023	2	-44	-16	-16	N/A
3/31/2023	1	-38	-19	-19	N/A
12/31/2022	1	-31	-22	-22	N/A
9/30/2022	0	-30	-18	-18	N/A
6/30/2022	0	-29	-14	-14	N/A
3/31/2022	7	-26	-16	-16	N/A
12/31/2021	13	-24	-17	-17	N/A
9/30/2021	14	-26	-22	-22	N/A
6/30/2021	14	-28	-27	-27	N/A
3/31/2021	10	-30	-27	-27	N/A
12/31/2020	7	-32	-26	-26	N/A
9/30/2020	10	-30	-27	-27	N/A
6/30/2020	14	-28	-29	-29	N/A
3/31/2020	20	-27	-27	-27	N/A
12/31/2019	27	-26	-26	-26	N/A
9/30/2019	35	-21	-39	-35	N/A
6/30/2019	44	-16	-53	-45	N/A
3/31/2019	53	-7	-33	-25	N/A
12/31/2018	62	1	-13	-5	N/A
9/30/2018	53	-2	17	21	N/A
6/30/2018	43	-5	47	47	N/A
3/31/2018	24	-14	28	28	N/A
12/31/2017	5	-22	8	8	N/A
9/30/2017	3	-22	N/A	-6	N/A
6/30/2017	0	-22	N/A	-20	N/A
3/31/2017	0	-23	N/A	-20	N/A
12/31/2016	0	-24	N/A	-19	N/A
9/30/2016	0	-22	N/A	-16	N/A
6/30/2016	0	-19	N/A	-13	N/A
3/31/2016	0	-16	N/A	-11	N/A
12/31/2015	0	-12	N/A	-10	N/A
9/30/2015	0	-10	N/A	N/A	N/A
6/30/2015	0	-9	N/A	-8	N/A
3/31/2015	N/A	-11	N/A	-7	N/A
12/31/2014	N/A	-14	N/A	-6	N/A
9/30/2014	N/A	-21	N/A	N/A	N/A
6/30/2014	N/A	-28	N/A	-10	N/A
3/31/2014	N/A	-24	N/A	-8	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Insufficient data to determine if POXEL's forecast earnings growth is above the savings rate (1.2%).

Winst versus markt: Insufficient data to determine if POXEL's earnings are forecast to grow faster than the French market

Hoge groeiwinsten: Insufficient data to determine if POXEL's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: Insufficient data to determine if POXEL's revenue is forecast to grow faster than the French market.

Hoge groei-inkomsten: Insufficient data to determine if POXEL's revenue is forecast to grow faster than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if POXEL's Return on Equity is forecast to be high in 3 years time

Poxel Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Forecast to breakeven in 2024

Consensus revenue estimates decrease by 43%

Consensus revenue estimates decrease by 13%

Consensus revenue estimates fall by 32%

Consensus forecasts updated

Price target decreased to €11.50

Recent updates

Poxel S.A., Annual General Meeting, Nov 28, 2024

Full year 2023 earnings released

New major risk - Financial data availability

New major risk - Shareholder dilution

New major risk - Shareholder dilution

Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in Japan

New major risk - Shareholder dilution

New minor risk - Financial data availability

New major risk - Revenue and earnings growth

Forecast to breakeven in 2024

New major risk - Share price stability

First half 2023 earnings released

Poxel S.A. to Report Q2, 2023 Results on Sep 26, 2023

Consensus revenue estimates decrease by 43%

Poxel S.A., Annual General Meeting, Jun 21, 2023

Consensus revenue estimates decrease by 13%

Consensus revenue estimates fall by 32%

Poxel S.A. to Report Q3, 2023 Results on Nov 08, 2023

Insufficient new directors

Consensus forecasts updated

First half 2022 earnings released

Poxel S.A. Announces Positive Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, A Novel, Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone

Price target decreased to €11.50

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Poxel S.A. Announces Pxl065 and Pxl770 Granted Orphan Drug Designation from the U.S. Fda for X Linked Adrenoleukodystrophy

Poxel S.A., Annual General Meeting, Jun 21, 2022

Price target decreased to €13.43

Insufficient new directors

Poxel Announces PXL770 Wins FDA Fast Track Designation for X-Linked Adrenoleukodystrophy

Insufficient new directors

Consensus revenue estimates fall by 28%

Poxel S.A. (EPA:POXEL) Analysts Just Trimmed Their Revenue Forecasts By 28%

Insufficient new directors

Poxel Announces PXL065 Granted FDA Fast Track Designation for X-Linked Adrenoleukodystrophy

First half 2021 earnings released

POXEL SA Completes Enrollment in Phase 2 NASH Trial for PXL065 (DESTINY-1) in Biopsy-Proven Patients

Poxel and Sumitomo Dainippon Pharma Announce Product Launch in Japan for TWYMEEG® as Treatment for Type 2 Diabetes

Poxel S.A. Announces New Strategic Direction with Increasing Focus on Rare Metabolic Diseases

Consensus forecasts updated

Poxel Presents Results of Two Clinical Studies on Its Direct Amp Kinase Activator, the Pxl770

Poxel SA and Sumitomo Dainippon Pharma Co., Ltd. Announces Approval of TWYMEEG for Treatment of Type 2 Diabetes in Japan

Poxel S.A. Presents New Results of Imeglimin Phase 2 and 3 Clinical Studies in Japan at the 64th Annual Meeting of the Japan Diabetes Society (JDS)

Is Poxel (EPA:POXEL) Weighed On By Its Debt Load?

Full year 2020 earnings released

New 90-day high: €7.62

Poxel S.A. Terminates Partnership Agreement with Metavant

Poxel S.A. to Report Q3, 2021 Results on Oct 20, 2021

Price target lowered to €15.83

How Much Did Poxel's(EPA:POXEL) Shareholders Earn From Share Price Movements Over The Last Five Years?

Poxel Announces Additional Positive Phase 2a Results, and Phase 2b Plan for PXL770, an Oral First-in-Class AMPK Activator, in NASH

Poxel Provides Update on Metavant Partnership with Imeglimin

Poxel Presents Phase 1b Clinical Results for PXL065 and New Preclinical Data for PXL770 at AASLD The Liver Meeting 2020

How Does Poxel's (EPA:POXEL) CEO Pay Compare With Company Performance?

New 90-day high: €7.19

New 90-day low: €6.00

Poxel Announces Positive Results From Phase 2a NASH Trial With PXL770, an Oral First-in-Class Direct AMPK Activator

Poxel S.A. Presents Imeglimin Phase 3 TIMES Results and PXL770 Preclinical Cardio-Renal Results at the 56th European Association for the Study of Diabetes Annual Meeting

First half earnings released

New 90-day low - €6.13

New 90-day low - €6.38

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven